Baker Bros. Advisors (RVMD) discloses 11.4M-share position in Revolution Medicines

Rhea-AI Filing Summary

Baker Bros. Advisors LP and related parties report passive ownership in Revolution Medicines, Inc. The reporting group, including Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and managing members Julian C. Baker and Felix J. Baker, reports beneficial ownership of 11,443,357 shares of Revolution Medicines common stock. This represents 5.3% of the company’s common stock, based on 214,242,688 shares outstanding as of June 30, 2026, as referenced from the issuer’s Form 10-Q. The shares are held by investment funds Baker Brothers Life Sciences, L.P. and 667, L.P., over which the Adviser has complete discretion. The reporting persons state they have sole voting and dispositive power over these shares and no shared voting or dispositive power.

Key Figures

Beneficially owned shares: 11,443,357 shares Ownership percentage: 5.3% Shares outstanding: 214,242,688 shares +2 more

5 metrics

Beneficially owned shares 11,443,357 shares Common Stock of Revolution Medicines beneficially owned by the reporting persons

Ownership percentage 5.3% Percentage of Revolution Medicines common stock class beneficially owned by reporting persons

Shares outstanding 214,242,688 shares Revolution Medicines common shares outstanding as of June 30, 2026

Sole voting power 11,443,357 shares Shares over which the reporting persons have sole power to vote or direct the vote

Sole dispositive power 11,443,357 shares Shares over which the reporting persons have sole power to dispose or direct disposition

Key Terms

beneficial ownership, sole voting power, sole dispositive power, Rule 13d-3, +1 more

5 terms

beneficial ownership financial

"The Reporting Persons beneficially own 11,443,357 shares of Common Stock directly held by the Funds"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole voting power financial

"The Reporting Persons have sole power to vote or direct the vote of 11,443,357 shares"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"The Reporting Persons have sole power to dispose or direct the disposition of 11,443,357 shares"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Rule 13d-3 regulatory

"Such percentage figures are calculated in accordance with Rule 13d-3 , as amended"

Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

FAQ

What percentage of Revolution Medicines (RVMD) does Baker Bros. Advisors report owning?

Baker Bros. Advisors and related reporting persons report 5.3% beneficial ownership of Revolution Medicines common stock, based on 214,242,688 shares outstanding as of June 30, 2026, as referenced from the company’s Form 10-Q.

How many Revolution Medicines (RVMD) shares does Baker Bros. Advisors beneficially own?

The reporting group beneficially owns 11,443,357 shares of Revolution Medicines common stock. These shares are directly held by Baker Brothers Life Sciences, L.P. and 667, L.P., with investment and voting discretion granted to Baker Bros. Advisors LP.

What is the basis for the 5.3% ownership figure in the RVMD Schedule 13G?

The 5.3% ownership is calculated under Rule 13d-3, using 214,242,688 Revolution Medicines common shares outstanding as of June 30, 2026, as reported in the company’s Form 10-Q filed on August 5, 2026.

Who are the reporting persons in the Revolution Medicines (RVMD) Schedule 13G?

The reporting persons are Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and individuals Julian C. Baker and Felix J. Baker. They may be deemed indirect beneficial owners of the shares held by affiliated investment funds.

Does Baker Bros. Advisors share voting or dispositive power over RVMD shares with others?

The filing states the reporting persons have sole voting power and sole dispositive power over 11,443,357 Revolution Medicines shares and report 0 shares with shared voting or shared dispositive power.

Which entities directly hold the Revolution Medicines (RVMD) shares reported in this Schedule 13G?

The 11,443,357 shares of Revolution Medicines common stock are directly held by Baker Brothers Life Sciences, L.P. and 667, L.P., with Baker Bros. Advisors LP having full discretion over investment and voting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:04 PM Accepted by SEC EDGAR 08/14/2026 - 04:01 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Revolution Medicines, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

76155X100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 76155X100

1

Names of Reporting Persons

Baker Bros. Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,443,357.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,443,357.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,443,357.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 76155X100

1

Names of Reporting Persons

Baker Bros. Advisors (GP) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,443,357.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,443,357.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,443,357.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

HC, OO

SCHEDULE 13G

CUSIP Number(s): 76155X100

1

Names of Reporting Persons

Julian C. Baker

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,443,357.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,443,357.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,443,357.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 76155X100

1

Names of Reporting Persons

Felix J. Baker

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,443,357.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,443,357.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,443,357.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Revolution Medicines, Inc.
(b)	Address of issuer's principal executive offices: 700 Saginaw Drive, Redwood City, CA 94063
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed by Baker Bros. Advisors LP (the "Adviser"), Baker Bros. Advisors (GP) LLC (the "Adviser GP"), Julian C. Baker and Felix J. Baker (collectively, the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The business address of each of the Reporting Persons is: c/o Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 10014 (212) 339-5690
(c)	Citizenship: The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 76155X100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Items 5 through 9 of each of the cover pages to this Schedule 13G are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock ("Common Stock") of Revolution Medicines, Inc. (the "Issuer") directly held in the aggregate by Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") which may be deemed to be indirectly beneficially owned by the Reporting Persons. The Reporting Persons beneficially own 11,443,357 shares of Common Stock directly held by the Funds. Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds' respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments. The Adviser GP is the sole general partner of the Adviser. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.
(b)	Percent of class: The information in Item 11 of each of the cover pages to this Schedule 13G is incorporated herein by reference. The percentage of beneficial ownership for each of the Reporting Persons reported herein and the information set forth below is based on 214,242,688 shares of Common Stock outstanding as of June 30, 2026, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 5, 2026. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The Reporting Persons have sole power to vote or direct the vote of 11,443,357 shares of Common Stock directly held by the Funds
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: The Reporting Persons have sole power to dispose or direct the disposition of 11,443,357 shares of Common Stock directly held by the Funds
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. The information in Item 4 is incorporated herein by reference.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Baker Bros. Advisors LP

Signature:	/s/ Scott L. Lessing
Name/Title:	Scott L. Lessing / President By: Baker Bros. Advisors (GP) LLC, its general partner
Date:	08/14/2026

Baker Bros. Advisors (GP) LLC

Signature:	/s/ Scott L. Lessing
Name/Title:	Scott L. Lessing/ President
Date:	08/14/2026

Julian C. Baker

Signature:	/s/ Julian C. Baker
Name/Title:	Julian C. Baker
Date:	08/14/2026

Felix J. Baker

Signature:	/s/ Felix J. Baker
Name/Title:	Felix J. Baker
Date:	08/14/2026

Exhibit Information

EXHIBIT 99.1 Joint Filing Agreement